640271-51-8

Usage

Uses

Used in Pharmaceutical Research and Development:
5-(4-Fluorophenyl)-3-nitro-2-pyridinylamine serves as an intermediate in the synthesis of a range of pharmaceuticals and agrochemicals. Its presence in these industries is attributed to its potential role in the development of new drugs and chemical compounds with therapeutic or agricultural benefits.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-(4-Fluorophenyl)-3-nitro-2-pyridinylamine is employed for its potential to contribute to the discovery and design of novel therapeutic agents. Its structural components may allow for the creation of molecules with specific biological activities, making it a valuable asset in drug development.
Used in Organic Synthesis:
5-(4-Fluorophenyl)-3-nitro-2-pyridinylamine is also utilized in organic synthesis, where it can be manipulated to form a variety of new chemical entities. Its versatility in chemical reactions makes it a useful building block for creating complex organic molecules with diverse applications.
Safety Precautions:
As with any chemical compound, it is crucial to exercise proper handling and safety measures when working with 5-(4-Fluorophenyl)-3-nitro-2-pyridinylamine. This ensures the protection of both the environment and the individuals involved in its synthesis and application.

Upstream product

• 1765-93-1 4-fluoroboronic acid 
• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 

Relevant academic research and scientific papers

SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted 1 H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS

The compounds of formula (I) in which R1, R2, R3 and R4 the meanings as given in the description are novel effective iNOS inhibitors.

NOVEL BENZIMIDAZOLE DERIVATIVES

A compound of the formula (I): (wherein A, B, C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is -N(S02R4)-, - N (COR5) - or -CO-; Y is -C (R6) (R7)_,-0- or -N (R8)_, provided that the compound (I) when E is nitrogen, n is 0, X is -CO-, and Y is -0- is excluded) is useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome, hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation (Pickwickian syndrome), sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, and increased anesthetic risk.